Table 2.
Cytotoxic activity data (μM) of 1 and 2.
| Compound | Cell Line | ||||
|---|---|---|---|---|---|
| Breast | Colon | Lung | Pancreas | ||
| MDA-MB-231 | HT-29 | NSLC A-549 | PSN1 | ||
| Bistratamide M (1) | GI50 | 18 | 16.0 | 9.1 | 9.8 |
| TGI | >20.0 | >20.0 | >20.0 | >20.0 | |
| LC50 | >20.0 | >20.0 | >20.0 | >20.0 | |
| Bistratamide N (2) | GI50 | >20.0 | 13.0 | 11.0 | 15.0 |
| TGI | >20.0 | >20 | >20.0 | >20.0 | |
| LC50 | >20.0 | >20 | >20.0 | >20.0 | |
| Doxorubicin | GI50 | 0.2 | 0.3 | 0.2 | 0.2 |
| TGI | 0.5 | 0.9 | 0.9 | 0.5 | |
| LC50 | 2.4 | >17.2 | >17.2 | 3.1 | |
GI50, compound concentration that produces 50% inhibition on cell growth as compared to control cells; TGI, compound concentration that produces total growth inhibition as compared to control cells, and LC50, compound concentration that produces 50% cell death as compared to control cells.